{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T07:09:21Z","timestamp":1779174561438,"version":"3.51.4"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T00:00:00Z","timestamp":1705190400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To understand the relative efficacy and safety of bimekizumab, a selective inhibitor of IL-17F in addition to IL-17A, vs other biologic and targeted synthetic DMARDs (b\/tsDMARDs) for PsA using network meta-analysis (NMA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A systematic literature review (most recent update conducted on 1 January 2023) identified randomized controlled trials (RCTs) of b\/tsDMARDs in PsA. Bayesian NMAs were conducted for efficacy outcomes at Weeks 12\u201324 for b\/tsDMARD-na\u00efve and TNF inhibitor (TNFi)-experienced patients. Safety at Weeks 12\u201324 was analysed in a mixed population. Odds ratios (ORs) and differences of mean change with the associated 95% credible interval (CrI) were calculated for the best-fitting models, and the surface under the cumulative ranking curve (SUCRA) values were calculated to determine relative rank.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The NMA included 41 RCTs for 22 b\/tsDMARDs. For minimal disease activity (MDA), bimekizumab ranked 1st in b\/tsDMARD-na\u00efve patients and 2nd in TNFi-experienced patients. In b\/tsDMARD-na\u00efve patients, bimekizumab ranked 6th, 5th and 3rd for ACR response ACR20\/50\/70, respectively. In TNFi-experienced patients, bimekizumab ranked 1st, 2nd and 1st for ACR20\/50\/70, respectively. For Psoriasis Area and Severity Index 90\/100, bimekizumab ranked 2nd and 1st in b\/tsDMARD-na\u00efve patients, respectively, and 1st and 2nd in TNFi-experienced patients, respectively. Bimekizumab was comparable to b\/tsDMARDs for serious adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Bimekizumab ranked favourably among b\/tsDMARDs for efficacy on joint, skin and MDA outcomes, and showed comparable safety, suggesting it may be a beneficial treatment option for patients with PsA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/kead705","type":"journal-article","created":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T03:52:54Z","timestamp":1705204374000},"page":"1779-1789","source":"Crossref","is-referenced-by-count":14,"title":["Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis"],"prefix":"10.1093","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J","family":"Mease","sequence":"first","affiliation":[{"name":"Swedish Medical Center and Providence St. Joseph Health, University of Washington , Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dafna D","family":"Gladman","sequence":"additional","affiliation":[{"name":"Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, University Health Network, University of Toronto , ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F","family":"Merola","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Harvard Medical School, Brigham and Women\u2019s Hospital , Boston, MA, USA"},{"name":"Division of Rheumatology, Department of Medicine, Harvard Medical School, Brigham and Women\u2019s Hospital , Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2571-788X","authenticated-orcid":false,"given":"Peter","family":"Nash","sequence":"additional","affiliation":[{"name":"School of Medicine, Griffith University , Brisbane, QLD, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacy","family":"Grieve","sequence":"additional","affiliation":[{"name":"Department of RWA Health Economics, Cytel, Inc , Waltham, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Laliman-Khara","sequence":"additional","affiliation":[{"name":"Department of RWA Health Economics, Cytel, Inc , Waltham, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damon","family":"Willems","sequence":"additional","affiliation":[{"name":"UCB Pharma , Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Taieb","sequence":"additional","affiliation":[{"name":"UCB Pharma , Colombes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam R","family":"Prickett","sequence":"additional","affiliation":[{"name":"UCB Pharma , Slough, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-663X","authenticated-orcid":false,"given":"Laura C","family":"Coates","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford and Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust , Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,1,13]]},"reference":[{"key":"2024070114110754900_kead705-B1","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024070114110754900_kead705-B2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2024070114110754900_kead705-B3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","article-title":"Psoriatic arthritis","volume":"7","author":"Fitzgerald","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2024070114110754900_kead705-B4","first-page":"1","article-title":"Treatment recommendations domain subcommittees. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"27","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2024070114110754900_kead705-B5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41584-022-00874-5","article-title":"Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy","volume":"19","author":"Najm","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2024070114110754900_kead705-B6","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The epidemiology of psoriatic arthritis","volume":"41","author":"Ogdie","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"2024070114110754900_kead705-B7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2024070114110754900_kead705-B8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special Article: 2018 American college of rheumatology\/national psoriasis foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2024070114110754900_kead705-B9","doi-asserted-by":"crossref","first-page":"5292","DOI":"10.1093\/rheumatology\/keab220","article-title":"What influences patients' opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international study","volume":"60","author":"Coates","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2024070114110754900_kead705-B10","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1007\/s13555-022-00770-6","article-title":"Demographic and clinical factors associated with patient-reported remission in psoriatic arthritis","volume":"12","author":"Gondo","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2024070114110754900_kead705-B11","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2024070114110754900_kead705-B12","author":"UCB Pharma S.A","year":"2023"},{"key":"2024070114110754900_kead705-B13","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F","volume":"11","author":"Adams","year":"2020","journal-title":"Front Immunol"},{"key":"2024070114110754900_kead705-B14","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/eji.201948138","article-title":"Presence, function, and regulation of IL-17F-expressing human CD4(+) T cells","volume":"50","author":"Burns","year":"2020","journal-title":"Eur J Immunol"},{"key":"2024070114110754900_kead705-B15","doi-asserted-by":"crossref","first-page":"5462","DOI":"10.4049\/jimmunol.179.8.5462","article-title":"Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F","volume":"179","author":"Kuestner","year":"2007","journal-title":"J Immunol"},{"key":"2024070114110754900_kead705-B16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2133.2008.08902.x","article-title":"Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin","volume":"160","author":"Johansen","year":"2009","journal-title":"Br J Dermatol"},{"key":"2024070114110754900_kead705-B17","doi-asserted-by":"crossref","first-page":"e001306","DOI":"10.1136\/rmdopen-2020-001306","article-title":"Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells","volume":"6","author":"Shah","year":"2020","journal-title":"RMD Open"},{"key":"2024070114110754900_kead705-B18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus Secukinumab in Plaque Psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"New Engl J Med"},{"key":"2024070114110754900_kead705-B19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet"},{"key":"2024070114110754900_kead705-B20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-alpha inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet"},{"key":"2024070114110754900_kead705-B21","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2024070114110754900_kead705-B22","author":"Higgins","year":"2019"},{"key":"2024070114110754900_kead705-B23","author":"National Institute for Health and Care Excellence","year":"2012"},{"key":"2024070114110754900_kead705-B24","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1017\/S0266462310000978","article-title":"Centre for Reviews and Dissemination databases: value, content, and developments","volume":"26","author":"Booth","year":"2010","journal-title":"Int J Technol Assess Health Care"},{"key":"2024070114110754900_kead705-B25","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2024070114110754900_kead705-B26","author":"Daly","year":"2021"},{"key":"2024070114110754900_kead705-B27","doi-asserted-by":"crossref","first-page":"F8","DOI":"10.1136\/archdischild-2018-315224","article-title":"Network meta-analysis explained","volume":"104","author":"Dias","year":"2019","journal-title":"Archi Dis Childhood Fetal Neonatal Ed"},{"key":"2024070114110754900_kead705-B28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.semarthrit.2017.02.001","article-title":"Switching biologics in the treatment of psoriatic arthritis","volume":"47","author":"Merola","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2024070114110754900_kead705-B29","year":"2014"},{"key":"2024070114110754900_kead705-B30","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1002\/sim.3680","article-title":"The BUGS project: evolution, critique and future directions","volume":"28","author":"Lunn","year":"2009","journal-title":"Stat Med"},{"key":"2024070114110754900_kead705-B31","author":"Dias","year":"2016"},{"key":"2024070114110754900_kead705-B32","author":"Dias","year":"2011"},{"key":"2024070114110754900_kead705-B33","author":"Dias","year":"2011"},{"key":"2024070114110754900_kead705-B34","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/rheumatology\/keab119","article-title":"Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis","volume":"60","author":"Mease","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2024070114110754900_kead705-B35","doi-asserted-by":"crossref","first-page":"e002074","DOI":"10.1136\/rmdopen-2021-002074","article-title":"Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes","volume":"8","author":"McInnes","year":"2022","journal-title":"RMD Open"},{"key":"2024070114110754900_kead705-B36","doi-asserted-by":"crossref","first-page":"e001117","DOI":"10.1136\/rmdopen-2019-001117","article-title":"Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis","volume":"6","author":"Ruyssen-Witrand","year":"2020","journal-title":"RMD Open"},{"key":"2024070114110754900_kead705-B37","author":"Pfizer Inc","year":"2022"},{"key":"2024070114110754900_kead705-B38","author":"Pfizer Inc","year":"2022"},{"key":"2024070114110754900_kead705-B39","author":"Abbvie Inc","year":"2023"},{"key":"2024070114110754900_kead705-B40","author":"AbbVie Deutschland GmbH & Co","year":"2023"},{"key":"2024070114110754900_kead705-B41","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus Adalimumab in Plaque Psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"N Engl J Med"},{"key":"2024070114110754900_kead705-B42","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"2024070114110754900_kead705-B43","doi-asserted-by":"crossref","first-page":"100601","DOI":"10.1016\/j.curtheres.2020.100601","article-title":"Network meta-analysis of tofacitinib, biologic disease-modifying antirheumatic drugs, and apremilast for the treatment of psoriatic arthritis","volume":"93","author":"Gladman","year":"2020","journal-title":"Curr Ther Res Clin Exp"},{"key":"2024070114110754900_kead705-B44","doi-asserted-by":"crossref","first-page":"e21447","DOI":"10.1097\/MD.0000000000021447","article-title":"Fourteen small molecule and biological agents for psoriatic arthritis: a network meta-analysis of randomized controlled trials","volume":"99","author":"Qiu","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"2024070114110754900_kead705-B45","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00296-017-3919-7","article-title":"Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis","volume":"38","author":"Kawalec","year":"2018","journal-title":"Rheumatol Int"},{"key":"2024070114110754900_kead705-B46","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3899\/jrheum.170449","article-title":"Minimal disease activity as a treatment target in psoriatic arthritis: a review of the literature","volume":"45","author":"Gossec","year":"2018","journal-title":"J Rheumatol"},{"key":"2024070114110754900_kead705-B47","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14102140","article-title":"Biologic disease-modifying antirheumatic drugs for preventing radiographic progression in psoriatic arthritis: a systematic review and network meta-analysis","volume":"14","author":"Wang","year":"2022","journal-title":"Pharmaceutics"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/kead705\/56253887\/kead705.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/7\/1779\/58378370\/kead705.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/7\/1779\/58378370\/kead705.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T18:08:10Z","timestamp":1719857290000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/7\/1779\/7529238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,13]]},"references-count":47,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,1,13]]},"published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kead705","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,1,13]]}}}